Citius Oncology (CTOR) Net Income towards Common Stockholders (2023 - 2026)
Citius Oncology (CTOR) posted quarterly Net Income towards Common Stockholders of -$26.6 million for Q1 2026, down 243.99% year-over-year from $18.5 million in Q1 2025, and down 380.83% quarter-over-quarter from -$5.5 million in Q4 2025.
Citius Oncology (CTOR) Net Income towards Common Stockholders (2023 - 2026) Analysis & Trends
Citius Oncology (CTOR) has reported Net Income towards Common Stockholders for 4 consecutive years, with -$26.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 243.99% year-over-year to -$26.6 million; the TTM figure through Mar 2026 stood at -$42.5 million (down 47.96% YoY), while the FY2025 annual figure was -$24.8 million, down 17.08% from the prior year.
- Net Income towards Common Stockholders fell to -$26.6 million in Q1 2026 per CTOR's latest filing, from -$5.5 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$147922.0 in Q1 2023 and bottomed at -$26.6 million in Q1 2026.
- Historically, Net Income towards Common Stockholders has averaged -$7.6 million across 4 years, with a median of -$5.5 million in 2025.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders sank 7083.92% — and 2025, when it soared 62.54%.
- Citius Oncology's Net Income towards Common Stockholders stood at -$4.7 million in 2023, then plunged by 40.86% to -$6.7 million in 2024, then advanced by 16.9% to -$5.5 million in 2025, then tumbled by 380.83% to -$26.6 million in 2026.
- Business Quant data shows CTOR's Net Income towards Common Stockholders at -$26.6 million in Q1 2026, -$5.5 million in Q4 2025, and -$5.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 710.19 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Citius Oncology | 80.25 Mn | 80.25 Mn | 1.00 Mn | -8.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.61 Mn |
| Dec 31, 2025 | -5.53 Mn |
| Sep 30, 2025 | -5.00 Mn |
| Jun 30, 2025 | -5.37 Mn |
| Mar 31, 2025 | -7.74 Mn |
| Dec 31, 2024 | -6.66 Mn |
| Jun 30, 2024 | -14.34 Mn |
| Mar 31, 2024 | -9.56 Mn |
| Dec 31, 2023 | -4.73 Mn |
| Sep 30, 2023 | -4.81 Mn |
| Jun 30, 2023 | -199,554.00 |
| Mar 31, 2023 | -147,922.00 |